Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIQ861 (treprostinil)
- Development stage
- Approved
- Lead developer
- Liquidia
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Treprostinil (investigational code LIQ861, brand name Yutrepia) is an inhaled dry powder formulation of treprostinil, a synthetic analog of prostacyclin. Developed by Liquidia Technologies (a subsidiary of Liquidia Corporation) using its proprietary PRINT (Particle Replication In Nonwetting Templates) technology, it produces uniform, precise drug particles designed for optimal deep-lung deposition via a palm-sized dry powder inhaler. Treprostinil acts as a prostacyclin receptor agonist, promoting pulmonary vasodilation and inhibiting platelet aggregation. It is FDA-approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
- Brand names
- Yutrepia
- Other names
- treprostinil inhalation powder
02
Targets
PTGIR (Prostanoid IP Receptor)PTGDR (Prostanoid DP1 receptor)PTGER1 (Prostaglandin E Receptor 1)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)PTGER2 (Prostaglandin E2 receptor EP2)PTGFR (Prostaglandin F2 alpha receptor)TYMP (Thymidine phosphorylase)
Beyond the preview
Go deeper on LIQ861 (treprostinil).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIQ861 (treprostinil).